• +1-646-491-9876
    • +91-20-67278686

    Search

    Progressive Multifocal Leukoencephalopathy-Pipeline Review H1 2017

    Progressive Multifocal Leukoencephalopathy-Pipeline Review H1 2017

    • Report Code ID: RW0001834324
    • Category Pharmaceuticals
    • No. of Pages 31
    • Publication Month May-17
    • Publisher Name Global Markets Direct
    Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017

    Summary

    Publisher's latest Pharmaceutical and Healthcare disease pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017, provides an overview of the Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline landscape.

    Progressive multifocal leukoencephalopathy (PML) is a demyelinating disease of the brain caused by lytic infection of oligodendrocytes by the JC polyomavirus. Symptoms include clumsiness, progressive weakness, and visual, speech, and sometimes personality changes. Risk factors include the presence of pathogenic JCV and an altered or weakened immune system, genetic or environmental factors.

    Report Highlights

    Publisher's Pharmaceutical and Healthcare latest pipeline guide Progressive Multifocal Leukoencephalopathy - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease) , complete with analysis by stage of development, drug target, mechanism of action (MoA) , route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

    The Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Progressive Multifocal Leukoencephalopathy and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Preclinical and Discovery stages are 5 and 3 respectively.

    Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

    Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

    Scope

    - The pipeline guide provides a snapshot of the global therapeutic landscape of Progressive Multifocal Leukoencephalopathy (Infectious Disease) .
    - The pipeline guide reviews pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
    - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
    - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
    - The pipeline guide reviews key companies involved in Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics and enlists all their major and minor projects.
    - The pipeline guide evaluates Progressive Multifocal Leukoencephalopathy (Infectious Disease) therapeutics based on mechanism of action (MoA) , drug target, route of administration (RoA) and molecule type.
    - The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
    - The pipeline guide reviews latest news related to pipeline therapeutics for Progressive Multifocal Leukoencephalopathy (Infectious Disease)

    Reasons to buy

    - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
    - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
    - Find and recognize significant and varied types of therapeutics under development for Progressive Multifocal Leukoencephalopathy (Infectious Disease) .
    - Classify potential new clients or partners in the target demographic.
    - Develop tactical initiatives by understanding the focus areas of leading companies.
    - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
    - Formulate corrective measures for pipeline projects by understanding Progressive Multifocal Leukoencephalopathy (Infectious Disease) pipeline depth and focus of Indication therapeutics.
    - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
    - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
    Table of Contents
    List of Tables
    List of Figures
    Introduction
    Publisher Report Coverage
    Progressive Multifocal Leukoencephalopathy - Overview
    Progressive Multifocal Leukoencephalopathy - Therapeutics Development
    Pipeline Overview
    Pipeline by Companies
    Products under Development by Companies
    Progressive Multifocal Leukoencephalopathy - Therapeutics Assessment
    Assessment by Target
    Assessment by Mechanism of Action
    Assessment by Molecule Type
    Progressive Multifocal Leukoencephalopathy - Companies Involved in Therapeutics Development
    Excision BioTherapeutics Inc
    Humabs BioMed SA
    Neurimmune Holding AG
    Neuway Pharma GmbH
    Pomona Ricerca SRL
    Progressive Multifocal Leukoencephalopathy - Drug Profiles
    EBT-103 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    IKT-01427 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    imatinib mesylate - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Monoclonal Antibody for JCV and BKV Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NI-307 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    NPW-007 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    PNJC-1 - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Small Molecules to Activate Sirtuin for Viral Infections - Drug Profile
    Product Description
    Mechanism Of Action
    R&D Progress
    Progressive Multifocal Leukoencephalopathy - Dormant Projects
    Progressive Multifocal Leukoencephalopathy - Product Development Milestones
    Featured News & Press Releases
    May 21, 2014: Inhibikase Therapeutics Receives Orphan Drug Designation for treatment of Progressive Multifocal Leukoencephalopathy
    Apr 25, 2013: Inhibikase Therapeutics To Present Data On IkT-001Pro At 5th International Congress On Polyomaviruses And Human Diseases
    Appendix
    Methodology
    Coverage
    Secondary Research
    Primary Research
    Expert Panel Validation
    Contact Us
    Disclaimer

    List of Tables

    Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Products under Development by Companies, H1 2017
    Number of Products by Stage and Target, H1 2017
    Number of Products by Stage and Mechanism of Action, H1 2017
    Number of Products by Stage and Molecule Type, H1 2017
    Progressive Multifocal Leukoencephalopathy - Pipeline by Excision BioTherapeutics Inc, H1 2017
    Progressive Multifocal Leukoencephalopathy - Pipeline by Humabs BioMed SA, H1 2017
    Progressive Multifocal Leukoencephalopathy - Pipeline by Neurimmune Holding AG, H1 2017
    Progressive Multifocal Leukoencephalopathy - Pipeline by Neuway Pharma GmbH, H1 2017
    Progressive Multifocal Leukoencephalopathy - Pipeline by Pomona Ricerca SRL, H1 2017
    Progressive Multifocal Leukoencephalopathy - Dormant Projects, H1 2017

    List of Figures

    Number of Products under Development for Progressive Multifocal Leukoencephalopathy, H1 2017
    Number of Products under Development by Companies, H1 2017
    Number of Products by Targets, H1 2017
    Number of Products by Stage and Targets, H1 2017
    Number of Products by Mechanism of Actions, H1 2017
    Number of Products by Stage and Mechanism of Actions, H1 2017
    Number of Products by Molecule Types, H1 2017
    Number of Products by Stage and Molecule Types, H1 2017
    Excision BioTherapeutics Inc
    Humabs BioMed SA
    Neurimmune Holding AG
    Neuway Pharma GmbH
    Pomona Ricerca SRL

    Request for Sample

    Report Url https://www.reportsweb.com//progressive-multifocal-leukoencephalopathy-pipeline-review-h1-2017&type=sample
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire before Buying

    Report Url https://www.reportsweb.com//progressive-multifocal-leukoencephalopathy-pipeline-review-h1-2017&type=buying
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments
     

    Inquire for Discount

    Report Url https://www.reportsweb.com//progressive-multifocal-leukoencephalopathy-pipeline-review-h1-2017&type=discount
    Report Name
    First Name
    Last Name
    Email
    Phone
    Company
    Job Title
    Country
    Publisher
    Report Code
    Comments